Edison Investment Research - Vectura Group PLC (VEC) Vectura - Not pausing for breath

Report

Edison Investment Research

Andy Smith

Vectura - Not pausing for breath

Building on its positive adjusted H118 EBITDA and its partnerships, Vectura has announced three recent additional developments. Partner Mundipharma received a positive EU opinion for flutiform (46% of H118 revenues) for the treatment of asthma in children, expanding its market from adults and adolescents. The agreement with Hikma to develop generic versions of GSKâ€™s Ellipta brings upfront and milestone payments and ensures Vecturaâ€™s participation in the global respiratory disease market irrespective of whether generic or branded products predominate in each market. The failure of VR475 in severe uncontrolled asthma reflects more the difficulty for a non-biologic product to treat these patients.

26/11/2018 2 EN

Underlying

Vectura Group PLC

Vectura Group is an inhaled airways disease focused business. Co. has a range of enabling formulations, analytics, process development and pre-commercial scale manufacturing capabilities. This integrated inhaled drug delivery platform enables the development of inhalation products and in particular for the treatment of airways diseases. Co. has three formulation and device technologies: dry powder inhalers, which include GyroHaler®, lever-operated inhaler, open-inhale-close inhaler, and unit-dose inhaler; pressurized metered dose inhalers, which include dose-indicating MDI actuator; and smart nebulizer technology, which includes AKITA® JET and FOX®.

See profile

GB00B01D1K48 United Kingdom

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Andy Smith

Other Reports on these Companies

Independent Investment Research

Monthly LMI Update Independent Investment Research

Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked. This compares to the total dividends of 5 cents per share in FY20. The Board has confirmed that, in...

August 6, 2021 August 6, 2021 10 EN

MarketLine

Acorda Therapeutics, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances And Investments

Summary Marketline's Acorda Therapeutics, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Acorda Therapeutics, Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitiv...

EUR 335.58

October 29, 2020 October 29, 2020 92 EN

GlobeNewsWire

Vectura Group plc: 2019 Preliminary ResultsÂ

Vectura Group plc: 2019 Preliminary Results 2019 Preliminary Results - Vectura reports 2019 financial performance ahead of expectations, with strong operational delivery - - Executing the strategy to become an industry-leading specialist inhalation CDMO - Chippenham, UK – 17 March 2020: Vectura Group plc (LSE: VEC) ("Vectura" or "the Group") today announces its preliminary results for the year ended 31 December 2019. Financial highlights 20192018% changeRevenue£178.3m£160.5m11.1%Gross profit£95.3m£98.9m(3.6%)R&D(£50.2m)(£55.5m)(9.5%)Adjusted EBITDA1£43.4m£39.0m11.3%Operating lo...

March 17, 2020 March 17, 2020 1 EN

OPAP - Winning strategy

OPAP enjoys a leading and growing position in the Greek and Cypriot gaming markets. The majority of its revenue, from land-based activities, is supported by exclusive prepaid licences. To complement these activities, OPAP has developed a strong presence in the regulated online markets, where, by definition, there is greater competition. Management’s strategy is to grow its customer interactions in both the online and offline worlds, through a combination of rejuvenating its older games and developing new games that appeal to broader demographics, while maintaining its leading corporate and soc...

December 20, 2024 December 20, 2024 1 EN

Pedro Fonseca

Pedro Fonseca

Patria Private Equity Trust - High liquidity and solid long-term track record

Patria Private Equity Trust’s (PPET’s) distributions from its primary fund investments have increased recently, supported by a revival in private equity (PE) deal activity. Its portfolio valuations continue to be validated by uplifts upon exits, which in the nine months to end-June 2024 averaged 23.3% (in line with the long-term average of 25%). Valuations and liquidity were also assisted by the successful £180m secondary sale in October 2024 at a limited 5% discount to carrying value. While PPET’s 12-month NAV total return (TR) to end-October 2024 (based largely on end-June 2024 valuations) w...

December 20, 2024 December 20, 2024 1 EN

Kate Heseltine

Kate Heseltine

MoneyHero - Emphasis on driving margin

MoneyHero’s Q324 results show revenues up 6% y-o-y (9M24 +18%) and a smaller adjusted EBITDA loss, as expected. The important element of the narrative, though, is the emphasis on driving revenues in higher-margin product areas and increasing operating efficiency within the business. Group CFO Hao Qian has resigned to return to China, with the group FD, Danny Leung, stepping up on an interim basis. The market opportunity remains substantial, and with customer data now on a unified platform, MoneyHero is well placed to deliver improved outcomes for both providers and end consumers. Our forecasts...

December 20, 2024 December 20, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Vectura - Not pausing for breath

Monthly LMI Update Independent Investment Research

Acorda Therapeutics, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances And Investments

Vectura Group plc: 2019 Preliminary ResultsÂ

OPAP - Winning strategy

Patria Private Equity Trust - High liquidity and solid long-term track record

MoneyHero - Emphasis on driving margin

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe